Second Line Capital’s Viking Therapeutics VKTX Stock Holding History

Second Line Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50,381	Closed	-$1.22M	–	159
2025 Q1	$1.22M	Buy	50,381 +870	+2%	+$27.5K	0.31%	49
2024 Q4	$1.99M	Buy	49,511 +11,393	+30%	+$650K	0.54%	41
2024 Q3	$2.41M	Buy	38,118 +9,699	+34%	+$569K	0.66%	34
2024 Q2	$1.51M	Buy	+28,419	New	+$1.86M	0.46%	46

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Second Line Capital's VKTX Position: Q2 2025 in Review

Second Line Capital sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 50,381 shares — an estimated $1.22M sold.

Second Line Capital first reported a position in VKTX in Q2 2024 and held it in 4 quarters. The position peaked at $2.41M in Q3 2024. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

Second Line Capital reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
Second Line Capital sold 50,381 Viking Therapeutics shares in Q2 2025, an estimated $1.22M.
Second Line Capital first reported a position in Viking Therapeutics in Q2 2024 and held it in 4 quarters.
Second Line Capital's Viking Therapeutics position peaked at $2.41M in Q3 2024.
391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Second Line Capital's 13F filing for Q2 2025, filed 18 Aug 2025.